Duality Advisers LP Invests $705,000 in Revvity, Inc. (NYSE:RVTY)

Duality Advisers LP purchased a new position in shares of Revvity, Inc. (NYSE:RVTY) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 6,448 shares of the company’s stock, valued at approximately $705,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. acquired a new position in shares of Revvity during the 3rd quarter worth $1,579,487,000. Ceredex Value Advisors LLC acquired a new position in shares of Revvity during the 4th quarter worth $108,353,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Revvity during the 4th quarter worth $33,568,000. Boston Trust Walden Corp acquired a new position in shares of Revvity during the 4th quarter worth $25,154,000. Finally, KBC Group NV acquired a new stake in Revvity in the 3rd quarter valued at about $25,301,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on RVTY. Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $88.00 to $125.00 in a research note on Thursday, January 4th. Stifel Nicolaus increased their price objective on shares of Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research note on Friday, February 2nd. Raymond James increased their price objective on shares of Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. UBS Group cut shares of Revvity from a “buy” rating to a “neutral” rating and increased their price objective for the company from $105.00 to $125.00 in a research note on Tuesday, January 16th. Finally, Barclays increased their price objective on shares of Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.91.

Insider Buying and Selling at Revvity

In other news, insider Prahlad R. Singh sold 21,217 shares of Revvity stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the sale, the insider now owns 92,801 shares in the company, valued at $9,677,288.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Revvity Trading Down 0.8 %

Shares of RVTY stock opened at $102.68 on Thursday. The stock has a market cap of $12.68 billion, a price-to-earnings ratio of 18.67, a price-to-earnings-growth ratio of 2.69 and a beta of 1.09. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. Revvity, Inc. has a fifty-two week low of $79.50 and a fifty-two week high of $133.26. The firm’s 50 day moving average price is $104.72 and its two-hundred day moving average price is $101.50.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.15 by $0.10. The firm had revenue of $695.90 million for the quarter. Revvity had a net margin of 25.20% and a return on equity of 7.41%. On average, analysts anticipate that Revvity, Inc. will post 4.65 EPS for the current year.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.